Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2446 to 2460 of 8909 results

  1. Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237

    In development Reference number: GID-TA10239 Expected publication date:  06 August 2026

  2. CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)

    In development Reference number: GID-HTE10085 Expected publication date: TBC

  3. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    Awaiting development Reference number: GID-TA11052 Expected publication date: TBC

  4. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

  5. Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]

    Awaiting development Reference number: GID-TA11198 Expected publication date: TBC

  6. Lifileucel for previously treated unresectable or metastatic melanoma ID3863

    In development Reference number: GID-TA10752 Expected publication date:  10 July 2026

  7. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

  8. Osteoporosis

    In development Reference number: GID-QS10188 Expected publication date: TBC

  9. AHEAD implants for external ear prosthesis

    Topic prioritisation

  10. Intradiscal oxygen-ozone treatment of symptomatic lumbar disc herniation

    Topic prioritisation

  11. Insertion of Stoma Preservation Device

    Topic prioritisation

  12. Botulinum Toxin injection prior to Abdominal wall reconstruction

    Topic prioritisation

  13. Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]

    Awaiting development Reference number: GID-TA11855 Expected publication date: TBC

  14. Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]

    In development Reference number: GID-TA11445 Expected publication date: TBC

  15. Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

    Awaiting development Reference number: GID-TA11686 Expected publication date: TBC